EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma

Fei Ma, Li-Yun Zheng, Dan-Jun Song, Zhong-Wei Zhao, Fei Cao, Wei-Yuan Hao, Jun-Qi Qiu, Dong Lu, Jia-Ping Zheng

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.123385 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Sorafenib and lenvatinib remain the standard first-line therapies for unresectable hepatocellular carcinoma (HCC); however, disease progression is nearly universal. Regorafenib has become a standard second-line agent based on the RESORCE trial. Immune checkpoint inhibitor (ICI), particularly programmed cell death-1 (PD-1) inhibitors, have further reshaped the therapeutic landscape. Preclinical studies have demonstrated that regorafenib may modulate the tumor immune microenvironment, thereby enhancing antitumor immunity. Nevertheless, robust real-world evidence evaluating the efficacy of regorafenib combined with PD-1 inhibitors after first-line failure remains limited. AIM To compare the clinical efficacy of regorafenib plus PD1 inhibitor vs monotherapy as a second-line treatment for patients with unresectable HCC. METHODS This study analyzed 140 advanced HCC patients who experienced disease progression after first-line therapy between February 2019 and August 2024. Patients were divided into two cohorts, the regorafenib plus PD1 inhibitor group [regorafenib plus PD1 inhibitor (RP) group, n = 101] and the regorafenib monotherapy group [regorafenib monotherapy (R) group, n = 39]. Clinical outcomes were evaluated using objective response rate, disease control rate (DCR), progression-free survival, and overall survival (OS). Subgroup analyses and multivariate Cox regression analysis were performed to identify prognostic factors. RESULTS The RP group achieved a higher DCR, with better control of both intrahepatic and extrahepatic lesions than the R group. Median PFS (5.4 months vs 2.7 months, P = 0.003) and OS (54.8 months vs 25.3 months, P = 0.041) were longer in the RP group. Patients with prior ICI exposure achieved longer OS with RP therapy (P = 0.006), whereas no significant OS difference was observed in ICI-naive patients. First-line treatment type (lenvatinib vs sorafenib) did not affect second-line outcomes. Multivariable analysis identified second-line PD-1 inhibitor therapy as an independent predictor of PFS, whereas no independent predictors of OS were identified. CONCLUSION For patients with unresectable HCC who fail first-line treatment, the combination of regorafenib and PD-1 inhibitors confers better survival benefits and disease control than regorafenib monotherapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →